Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Grows By 51.2%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 263,391 shares, a growth of 51.2% from the January 29th total of 174,243 shares. Based on an average daily trading volume, of 72,785 shares, the short-interest ratio is currently 3.6 days. Approximately 9.9% of the shares of the company are sold short. Approximately 9.9% of the shares of the company are sold short. Based on an average daily trading volume, of 72,785 shares, the short-interest ratio is currently 3.6 days.

Alzamend Neuro Stock Down 3.4%

ALZN stock opened at $2.01 on Friday. The company has a 50-day simple moving average of $2.07 and a 200 day simple moving average of $2.24. The company has a market capitalization of $7.64 million, a P/E ratio of -0.61 and a beta of -0.24. Alzamend Neuro has a fifty-two week low of $1.58 and a fifty-two week high of $10.17.

Alzamend Neuro (NASDAQ:ALZN) last released its earnings results on Tuesday, December 9th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.53. Equities analysts anticipate that Alzamend Neuro will post -1.68 EPS for the current year.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently raised its position in Alzamend Neuro stock. Geode Capital Management LLC boosted its position in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 33.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,506 shares of the company’s stock after purchasing an additional 6,928 shares during the period. Geode Capital Management LLC owned approximately 0.72% of Alzamend Neuro worth $50,000 as of its most recent SEC filing. Institutional investors and hedge funds own 49.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ALZN shares. Ascendiant Capital Markets reduced their price target on shares of Alzamend Neuro from $42.00 to $28.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alzamend Neuro in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.